Therapy Areas: AIDS & HIV
US President's chief adviser expects key data on J&J and Moderna COVID-19 boosters shots in a few weeks
20 September 2021 -

Dr Anthony Fauci, Director of the US National Institute of Allergy and Infectious Diseases and the US President's chief medical adviser, said on Sunday that the data needed to determine the advisability of booster shots of the Moderna Inc (Nasdaq:MRNA) and Johnson & Johnson (NYSE:JNJ) COVID-19 vaccines is just weeks away, Reuters news agency reported on Monday.

On 17 September 2021, a US Food and Drug Administration advisory panel had recommended a third shot of the two-dose Pfizer (NYSE:PFE)/BioNTech (Nasdaq:BNTX) COVID-19 vaccine for people age 65 and older or at high risk of severe COVID-19, but declined to endorse boosters for the wider population.

People who have received the two-dose Moderna vaccine or one-dose J&J vaccine are still awaiting guidance on possible booster shots.

Dr Fauci added that more data may also show a broader need for booster shots across the general US population.

Health officials reportedly indicated that they expected boosters would ultimately be recommended for a broad range of the population, but urged Americans not to seek booster doses until FDA approval is received.

Login
Username:

Password:


Related Headlines

Lilly to Supply 614,000 Additional Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab to the US government for the Treatment or Post-Exposure Prevention of COVID-19

Adaptive Phage Therapeutics Inks Agreement with ARLG to Support Phase 1b/2 Cystic Fibrosis Study

Venatorx Pharmaceuticals Forges Collaboration with Roche to Develop New Class of Antibiotics targeting WHO Critical Priority Pathogen

Axial Therapeutics Receives FDA Clearance of IND Application and Initiates Phase 2b Trial for AB-2004, Lead Gut-Targeted, Molecular Therapeutic for the Treatment of Irritability in Autism Spectrum Disorder

Axial Therapeutics Receives FDA Clearance of IND Application and Initiates Phase 2b Trial for AB-2004, Lead Gut-Targeted, Molecular Therapeutic for the Treatment of Irritability in Autism Spectrum Disorder

Axial Therapeutics Receives FDA Clearance of IND Application and Initiates Phase 2b Trial for AB-2004, Lead Gut-Targeted, Molecular Therapeutic for the Treatment of Irritability in Autism Spectrum Disorder

US likely to make available COVID-19 vaccines for children between five to 11 in November 2021

US President's chief medical adviser says US can prevent another COVID-19 surge with higher vaccination rates

The IMA Group strengthens and broadens clinical research offerings via acquisition of DXRG

US FDA Approves Ocular Therapeutix Supplemental New Drug Application for Dextenza 0.4 mg for Intracanalicular Use for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis

Vedanta Touts Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of USD 23.8m Option by BARDA

First Patient Dosed in Phase 3 NIH ACTIV-2 Trial Evaluating SAB-185 for Treatment of COVID-19

SAB Biotherapeutics doses first COVID-19 patient under Phase 3 SAB-185 NIH ACTIV-2 trial

Malaysia's drugs regulator approves Sinovac's COVID-19 vaccine for 12-17 year olds

SAB announces interim analysis of SAB-185 in phase 2 part of ACTIV-2 study in hospitalized patients with mild to moderate COVID-19